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Background: An effective malaria vaccine remains elusive. The most effective experimental vaccines confer only
limited and short-lived protection despite production of protective antibodies. However, immunization with irradiated
sporozoites, or with live sporozoites under chloroquine cover, has resulted in long-term protection apparently due to
the generation of protective CD8+ T cells. The nature and function of these protective CD8+ T cells has not been
elucidated. In the current study, the phenotype of CD8+ T cells generated after immunization of C57BL/6 mice with live
Plasmodium berghei sporozoites under chloroquine cover was investigated.
Methods: Female C57BL/6 mice, C57BL/6 mice B2 macroglobulin −/− [KO], or invariant chain−/− [Ic KO] [6–8 weeks
old] were immunized with P. berghei sporozoites and treated daily with 800 μg/mouse of chloroquine for nine days.
This procedure of immunization is referred to as “infection/cure”. Mice were challenged by inoculating intravenously
1,000 infectious sporozoites. Appearance of parasitaemia was monitored by Giemsa-stained blood smears.
Results: By use of MHC I and MHC II deficient animals, results indicate that CD8+ T cells are necessary for full
protection and that production of protective antibodies is either CD4+ T helper cells dependent and/or lymphokines
produced by CD4 cells contribute to the protection directly or by helping CD8+ T cells. Further, the phenotype of
infection/cure P. berghei responsive CD8+ T cells was determined to be KLRG1high CD27low CD44high and CD62Llow.
Conclusion: The KLRG1high CD27low CD44high and CD62Llow phenotype of CD8+ T cells is associated with protection
and should be investigated further as a candidate correlate of protection.Background
While reduction in malaria cases has been reported in
many countries, malaria remains among the world’s
most prevalent and fatal infectious disease. In 2011, it
was estimated there were 216 million malaria episodes
and 655,000 malaria deaths [1]. With the majority of the
deaths occurring in children less than five years of age,
and with almost half of the world population at risk, an
effective vaccine against malaria is urgently needed [2].
Natural exposures to malaria infections do not immedi-
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unless otherwise stated.in endemic areas susceptible to multiple episodes of the
disease. Eventually, partial immunity is acquired in older
children and adults, affording them protection against clin-
ical symptoms and/or severe disease. However, protection
is not sterile [3] and the immune responses to Plasmodium
parasites are short-lived [4]. This is attributed to short half-
life of protective antibodies [4] and to a cellular response
[5-7] too weak to grant protection [8-11]. Sterile protection
has however been achieved experimentally in both animal
models of malaria and in malaria-naive humans immu-
nized with whole live sporozoites [12].
Intravenous administration of irradiated sporozoites ren-
ders long-lasting protection [13-17] by a mechanism medi-
ated largely by CD8+ T cells [18-23]. Although there is
data in favour of other mechanisms [24] and different mice
strains show different susceptibility to malaria [25,26],Ltd. This is an Open Access article distributed under the terms of the Creative
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tection. Evidence of protection conferred by immunization
with sporozoites under chloroquine (CQ) cover was ini-
tially demonstrated in mice and rats using Plasmodium
berghei [27,28]. More recently, infection under CQ cover
has also been shown to induce long-lasting protection in
malaria-naïve human [29,30] and murine models [31,32].
In these models, CD8+ T cells appear to play an important
role in protection [24,29-32]. Taken together, these data
suggest that while natural exposure elicits weakly protect-
ive humoral and cellular immunity, strategies such as in-
oculation of irradiated sporozoites or viable sporozoites
under CQ cover induce CD8+ T cells which, alone or in
combination with antibodies, provide long-lasting protec-
tion. A better understanding of the mechanics of these pro-
tective cells is fundamental to vaccine development efforts.
In this study, P. berghei murine model was used to
characterize the phenotype of CD8+ T cells generated
under CQ cover and to associate these phenotypes with
protection from a lethal challenge.
Methods
Mice
Female C57BL/6 mice, C57BL/6 mice B2 macroglobulin
−/− (KO), or invariant chain−/− (Ic KO) (6–8 weeks old)
were purchased from the Jackson Laboratory (Bar Harbor,
ME). These animals were housed at the Walter Reed Army
Institute of Research (WRAIR) animal facility and handled
according to institutional guidelines. All procedures were
reviewed and approved by the WRAIR Animal Care and
Use Committee (IACUC) and were performed in a facility
accredited by the Association for Assessment and Accredit-
ation of Laboratory Animal Care International. Euthanasia
methods were compliant with the approved IACUC proto-
col, with frequent supervision by the institute’s veterinary
team. After the animals were challenged, strict humane
endpoints criteria were adhered to by frequently monitor-
ing the health of the animals in order to avoid or terminate
unrelieved pain and/or distress. Animals positive for para-
sitaemia for two consecutive days were euthanized before
showing distress and/or pain by inhalation of CO2 from a
pressurized tank in a chamber. This was followed by cer-
vical dislocation prior to disposal of the dead mice.
Sporozoites
Sporozoites (Spz) from P. berghei ANKA strain were ex-
tracted from salivary glands of Anopheles stephensi mosqui-
toes 16–21 days post blood meal as previously described
[19]. Mosquitoes were maintained in the WRAIR Entomol-
ogy Branch Insectary facilities.
Reagents, antibodies and chemicals
Cell media and CFSE were purchased from Life Technolo-
gies (Carlsbad, CA). Purified antibodies or fluorochromelabeled antibodies were purchased from eBioscience (San
Diego, CA). Brefeldine A, Giemsa stain and CQ were pur-
chased from Sigma (St. Louis, MO).
Immunization and treatment
Experimental animals were inoculated two or three times
intravenously with 10,000 or 20,000 Spz (in 100 ul PBS),
ten days apart and treated daily with 800 μg/mouse (100 ul
in PBS) of CQ, administered intraperitoneally (i.p.), starting
from the day of the first inoculation until nine days post
last inoculation. This procedure of immunization is re-
ferred to as “infection/cure”. For the CQ control group, the
same regimen of CQ as that of the experimental group was
administered with the exception that these animals were
not inoculated with Spz. The absolute control group re-
ceived PBS only.
Challenge and assessment of protection
For challenge experiments, mice were inoculated intra-
venously with 1000 infectious Spz. Challenge was per-
formed at two weeks post suspension of CQ treatment.
Appearance of parasitaemia was monitored by Giemsa-
stained blood smears. Animals free of parasitaemia for
two weeks were considered protected.
Lymphocyte preparation
Mice were euthanized by CO2 inhalation as described
above. Livers and spleens were removed, and livers were
perfused with 10 ml PBS. Single cell suspensions of lym-
phocytes were made from both organs (liver infiltrating
lymphocytes and splenocytes). Cells were re-suspended
in PBS and used for analysis or transfer. Peripheral blood
for blood lymphocyte analysis was collected from the tail
vein in a heparinized vial.
Serum and splenocyte transfer
Recipient mice in transfer experiments received either
500 μL/mouse of undiluted serum intraperitoneally,
20 × 10^6 splenocytes re-suspended in 500 μL of PBS by
injection into the tail vein, or a combination of both.
Flow cytometry analysis
Analysis was performed with an LSR II cytometer
(Beckon Dickinson San Diego, CA) and data were ana-
lysed with Flow-Jo software (BD). The panel of fluoro-
chrome conjugated antibodies for flow cytometry
included: CD3- PrcP, CD4-Pacific Blue, CD8-V500 or
Pacific Orange, CD45RB or CD44- Alexa fluoro −700,
CD27-APC, CD127 –PE, KLRG-1 FITC. When the
intracellular cytokine IFNγ was tested, the panel used
was: CD8-PO, KLRG-1-FITC, CD62-PrCPcy5.5, CD44
Alexa-700, CD27-APC, IFN- γ-PE. In all assays UV-
viability dye was included. Flow cytometry antibodies
were purchased from Life Technologies (Carlsbad, CA).
Figure 1 Infection with sporozoites under chloroquine cover
induces long lasting protection. Infection with sporozoites under
CQ cover induces long lasting protection. Three groups of ten mice
each were inoculated three times, two weeks apart with 20,000 Spz.
Each group of animals was challenged once with 1,000 sporozoites-at
week 4, 8, 12 and 16 post the last inoculation as shown. For each
group five naïve mice were used as infectivity controls. Appearance of
parasitaemia was followed by Giemsa staining of blood smears.
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Allophycocyanin (APC), Pyridine-chlorophyll proteins-
Cy-5 (PrCP-Cy5), Phycoerythrin (PE), Fluorescein (FITC).
Antibodies are indicated by the marker recognized-
fluorochrome, e.g. anti CD3 Fluorescein-conjugated was
CD3-FITC.
Results
Three cycles of infection/cure results in protection
To establish the infection and cure model of C57BL/6
mice, animals were inoculated with infective Spz in
the presence of CQ as described in the method sec-
tion, referred to as infection/cure. Different dose and
frequency regimens of infection/cure were compared
(Table 1). Three groups of animals were challenged 4, 8
or 16 weeks post the last inoculation. Animals whose
blood was negative for parasitaemia at 14 days post chal-
lenge were declared protected. One hundred percent of
the animals that received three-inoculations of 20,000
Spz remained fully protected when challenged eight
weeks post third inoculation, whereas those challenged
16 weeks post third inoculation exhibited only 40%
protection (Figure 1). All animals treated with CQ (but
not inoculated with Spz) and challenged two weeks
post suspension of the CQ treatment became parasit-
aemia confirming a lack of a residual protective effect of
CQ following suspension of the drug. This data indicates
infection/cure immunization with three, 20,000 Spz inoc-
ulations resulted in protection.
Protection requires both CD8+ T cells and antibodies
To investigate the relative role played by the cellular and
humoral immune response in protection from the chal-
lenge, spleens and serum were collected from infection/
cure animals two weeks after suspension of CQ treat-
ment and transferred into naïve animals. Groups of 10
naïve C57BL/6 mice were given either splenocytes,
serum or both as described in the methods section. Re-
cipient animals were challenged 24 h post-transfer and
parasitaemia monitored for two weeks. Ninety percent
of the animals treated with both splenocytes and im-
mune serum were protected. Animals that received sple-
nocytes or immune serum alone showed 50% and 60%
protection respectively (Figure 2A). This data points to
an additive protective effect of cellular and humoral im-
munity. Having demonstrated that cellular immunityTable 1 Immunization regimen with Spz used for
infection/cure of mice (10 animals/group)
Spz (dose) Immunizations (n) Protection (%)
10,000 3 80
20,000 2 40
20,000 3 100was required to grant 100% protection, the role of CD4+
T cells and CD8+ T cells in protection using Ic−/− (MHC
II KO, CD4+ cell deficient) and β2 microglobulin−/−
(MHC I KO, CD8 + cell deficient) mice was investigated.
Immunized or non-immunized groups of 10 C57BL/6,
MHC II KO or MHC I KO mice were challenged two
weeks after suspension of the CQ treatment. As expected,
wild type C57BL/6 mice were fully protected whereas
MHC II KO and MHC I KO animals were only partially
protected (Figure 2B). These results indicate that CD8+ T
cells are necessary for full protection and that production
of protective antibodies is either CD4+ T helper cells
dependent and/or lymphokines produced by CD4 cells
contribute to the protection directly or by helping CD8+
T cells.
The phenotype of infection/cure P. berghei responsive
CD8+ T cells is KLRG1high CD27low CD44high and CD62Llow
In order to identify the phenotype of CD8+ T cells gener-
ated during this infection/cure under CQ cover regimen,
splenocytes and peripheral blood from mice three weeks
post last inoculation for the presence of CD8+, CD3+,
CD11a, CD127, CD27, KLRG1, CD44 and CD62L cells by
flow cytometry was analysed. Circulating peripheral lym-
phocytes of infection/cure mice had about six-fold higher
percent of CD8+ T cells containing KLRG1high, CD27low
compared to controls (Table 2) with p value of control
group vs. infection/cure group at <0.0001. Figure 3 shows
a representative experiment where splenocytes and per-
ipheral blood lymphocytes were analysed. Analysis of the
CD8+ KLRG1high, CD27low cell population had high ex-
pression of CD44 and low expression of CD62L (Figure 4).
A B
Figure 2 CD4+ T cells and CD8+ T cells are required for full protection. A) Infection/cure animals were sacrificed two weeks post
suspension of CQ treatment. Splenocytes and/or serum from immunized or non-immunized animals were harvested and transferred into naïve
C57BL/6 mice. Groups of ten recipient mice received 2 × 107 cells, 100 μL serum or a combination of both. Twenty-four hours later animals were
challenged with 1000 Spz and appearance of parasitaemia was monitored for two weeks (representative of two experiments). B) Ten C57BL/6
wild type, or Ic−/−(MHC II KO), or β2 macroglobulin −/− (MHC I KO) were infected/cured under CQ cover as described, group of animals received
CQ alone as a control ( results from one experiment). Two weeks post suspension of the CQ treatment animals were challenged with 1,000 Spz
and the appearance of parasitaemia monitored for two weeks.
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increased populations of effector memory CD8+ T cells.
Results in Figures 3 and 4 are representative of three ex-
periments with a pool of three spleens (splenocytes) or
three experiments with 5–7 animals per group for the per-
ipheral blood lymphocytes (peripheral blood). Statistical
analysis for peripheral blood is reported in Table 2.
Identifying T cell phenotype associated with protection
To investigate whether the phenotype CD8+ KLRG1high,
CD27low, CD44high, CD62Llow is associated with protec-
tion, partial protection conferred by a two immunization
regimen with 20,000 Spz (Table 1) was used. Twelve
C57BL/6 mice were immunized twice with 20,000 Spz.
For controls, three animals were injected with CQ only.
Two weeks after suspension of CQ treatment, circulating
peripheral blood was collected from individual mice.
The presence of CD8+ KLRG1high, CD27low cells was
analysed. Animals were challenged and the appearance
of parasitaemia monitored for two weeks. Expression ofTable 2 CD8+ T cells containing KLRG1high, CD27low phenotyp
Group Mean CD8+ KLRG1high,
CD27low cells (%)
95% CI of me
Lower
Control (15) 1.04 0.73
Post-3 (22) 5.72 4.41
Post-1 (5) 1.30 0.95
Infection/cure animals were inoculated three times (post-3) or one time with 20,000 Sp
KLRG1high, CD27low phenotype in the circulating peripheral lymphocytes. Statistical sig
in each experiment per group are shown in brackets. There was significant difference
(p = 0.0013). There was no significant difference between control vs. post-1 groups. Th
of blood.KLRG1high, CD27low was significantly higher in pro-
tected animals compared to non-protected or controls
with a p-value of 0.0087 and 0.024 respectively (Table 3),
suggesting that CD8+, KLRG1high, CD27low, CD44high,
CD62Llow cells were associated with protection.
Discussion
Little progress has been made in elucidating the require-
ment for immune protection against malaria infection.
Protection has not been achieved even with high titers of
antibodies against known liver antigen [33], blood stage
antigen [34,35] or antigen specific CD8+ T cells produced
with adenovirus immunization [36]. In addition, human
immunization with irradiated sporozoites has shown lim-
ited success unless sporozoites are injected intravenously
[37]. Conversely, immunization with irradiated sporozo-
ites or live sporozoites under CQ cover induces protection
[29,31]. In the current study, the infection/cure C57BL/6
mouse model was used to elucidate the immune protec-
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Figure 3 Identification of CD8+ T cells phenotype generated during the infection/cure. Splenocytes (top panels) or peripheral blood
(bottom panels) from naïve (left panels) or infection/cure (right panel) animals were harvested three weeks post last inoculation. Total
lymphocytes were extracted, and stained as described in methods section. Total lymphocytes, were gated on CD8+ T cells and analysed for the
presence of KLRG1, and CD27.
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both CD4+ T cells and CD8+ T cells are necessary to me-
diate immunity to liver stage malaria parasites [31,32].
This was demonstrated by immunizing BALB/c mice with
Plasmodium yoelii iRBC under CQ cover and then treat-
ing with depleting antibodies against CD4+ T cells and
CD8+ T cells. In this study, the infection/cure CD8+ T
cells deficient (MHC I KO) mice resulted in only partial
protection from lethal challenge, thus implicating CD8+ T
cells in protection. Passive transfer with serum or cell
alone also failed to confer 100% protection, thus indicating
the cooperation of antigen specific cells and antibodies ingranting protection. MHC II animals were also only par-
tially protected. The most likely explanation is that the
protective antibodies generated during infection/cure need
CD4+ T cell help, which is lost in CD4+ T cell deficient
animals. However, the role of CD4+ T cell in this model
cannot be excluded is also to support the generation of
protective CD8+ T cells or that they are directly involved
in parasite killing. It will be interesting to perform transfer
experiments to test the protective effect of serum from in-
fection/cure MHC II animals enriched with CD4+ T cells
from infection/cure wildtype animals. This will be import-













































Figure 4 Identification of CD8+ T cells phenotype generated during the infection/cure. Splenocytes from infection/cure animals were
gated on CD8+ KLRG1high, CD27low cells, and analysed for the level of expression of CD62L and CD44 experiments which were representative of
3 experiments with five mice in each group.
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volved in anti-plasmodium activity. From this study and
that by Belnoue et al., data strongly suggest that both a
humoral response and CD8+ T cells are required for im-
munity to liver stage P. berghei parasites [31,32].Table 3 Mean CD8+ KLRG1high, CD27low T cell (%)
expressed in circulating peripheral blood of control,
protected and non-protected animals
Group Mean CD8+ KLRG1high,
CD27low cells (%)
95% CI of mean
Lower Upper
Control (3) 1.117 0.3696 1.864
Protected(6) 5.772 3.759 7.785
Non-protected (6) 2.385 1.563 3.207
Twelve C57BL/6 mice were immunized twice with 20,000 Spz. Six mice were
protected and six were not protected. Statistical significance was determined
using Mann Whitney test. The numbers of animals used in each group are
shown in brackets. There was significant difference between the control vs.
protected groups (p = 0.024) and protected vs. non-protected (p = 0.0087).
There was a marginal significant difference between control vs.
non-protected (p = 0.0476).In an effort to further elucidate immune protection,
CD8+ T cells in peripheral blood and splenocytes were
characterized. The distinct populations of CD8+ T cells
with phenotype KLRG1high, CD27low, CD44high, CD62Llow
were shown to be associated with protection. This popula-
tion is absent in the intrahepatic lymphocytes. In the clas-
sical model of protection by immunization with irradiated
sporozoites, the putative protective CD8+ T cells are
found mostly in the liver [18,19] and produce IFNγ. In a
recent study, Nganou-Makandop et al. [21] reported com-
parable levels of hepatic CD8+ T cells with a CD44high,
CD62Llow phenotype that produce IFNγ in response to
PMA/Iono. In this study, mice were either immunized
with radiation-attenuated sporozoites or infected with
P. berghei under CQ cover. In the current study, the
CD8+ KLRG1high, CD27low, CD44high, CD62Llow pheno-
type that was associated with protection was not present
in the liver of immunized animals. A possible explanation
of the apparent discrepancy is that more than one popula-
tion of CD8+ T cells contributes to protection. One can
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CD44high, CD62Llow cells and the intrahepatic CD8+
CD44high, CD62Llow cells are the same antigen specific
population whose phenotype and organ-homing is modu-
lated by antigen exposure. In explorative experiments, it
was observed that splenic and peripheral blood CD8+
KLRG1high, CD27low, CD44high, CD62Llow T cells respond
to in vitro stimulation with anti CD3 and in vivo sporozo-
ites infection by producing IFNg (see Additional file 1:
Figure S1 and Figure S2). This is consistent with CD8+
KLRG1high, CD27low, CD44high, CD62Llow T cells partici-
pating to protection by producing IFNg. However, these
cells do not account for all the IFNg produced in response
to in vitro stimulation with anti CD3 (see Additional file 1:
Figure S1 and Figure S2), or in vivo stimulation with spo-
rozoites see Additional file 1: Figure S1 and Figure S2). It
is, therefore, conceivable that other CD8+ T cells with low
expression of KLRG1 are generated during this infection/
cure regimen. Such cells respond to sporozoite infection
with IFNg production and display an elevated ability to re-
spond to T cell receptor triggered by releasing IFNg. The
role of this CD8+ T cell phenotype in protection remains
to be determined. KLRG1 has been shown to down regu-
late T cell receptor signaling [38,39], thus suggesting that
the acquisition of the KLRG1high phenotype is important
for effector memory population after antigen encounter
and execution of effector function.
Conclusions
KLRG1high, CD27low, CD44high, CD62Llow are the circu-
lating CD8+ T cells generated during infection which are
associated with protection and thus represent a correlate
of protection. Passive transfer of purified/enriched
KLRG1high, CD27low, CD44high, CD62Llow CD8+ T cells
will be critical in demonstrating a direct correlation of
this phenotype in protection.
Additional file
Additional file 1: Interferon produced by CD8+ KLRG1high, CD27low.
Infection/cure animals were challenged with 1,000 sporozoites three
weeks post third immunization. Twenty four hours later, animals were
injected with 100 μg of Brefeldine A to prevent lymphokines secretion.
Five hours later animals were euthanized and blood collected by cardiac
puncture. Five naïve mice were used as controls. Blood from 5 naïve or 5
infection/cure animals was pooled together, red blood cells were lysed
and the peripheral lymphocytes incubated in the presence of media
control of 5 μg/ml of anti CD3 antibody 2C11. Sixteen hours later cells
were washed and stained for CD3, CD8, KLRG1, CD27 and IFNγ. Figure
S1) Peripheral blood lymphocytes were gated on CD8+ KLRG1high,
CD27low and analyzed for IFNγ produced by CD8+ KLRG1high, CD27low.
Figure S2) Splenocytes from animal infection/cure were labeled with
CFSE, transferred into naïve mice and then challenged with 1,000 Spz
24hr post transfer. Forty-eight hours post challenge animals were euthanized
and splenocytes harvested and analyzed for the production of IFNγ by
transferred (immune cells) and recipient’s (naïve) cells. CFSE+ (transferred/
immune) or CFSE- (naïve) cells were gated on CD8+, CD27low and analyzed
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